Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT00946647
Title A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

acute myeloid leukemia

myelodysplastic/myeloproliferative neoplasm

Therapies

Panobinostat

Azacitidine

Age Groups: adult
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Georgia Health Sciences University Dept. of MCG Augusta Georgia 30912 United States Details
Goshen Center for Cancer Care IU Cancer Center Indianapolis Indiana 46202 United States Details
University of Kansas Hospital and Medical Center SC - Univ KS Kansas City Kansas 66160 United States Details
Dana Farber Cancer Institute Beth Israel Deaconess Med Ctr Boston Massachusetts 02215 United States Details
Memorial Sloan Kettering Sloan Kettering 2 New York New York 10017 United States Details
Cleveland Clinic Foundation Cleve Clinic Cleveland Ohio 44195 United States Details
Medical University of South Carolina -Hollings Cancer Center MUSC Charleston South Carolina 29425 United States Details
University of Texas MD Anderson Cancer Center Dept of MD Anderson (16) Houston Texas 77030 United States Details
Novartis Investigative Site Innsbruck A-6020 Austria Details
Novartis Investigative Site Vienna A-1100 Austria Details
Novartis Investigative Site Brugge 8000 Belgium Details
Novartis Investigative Site Yvoir 5530 Belgium Details
Novartis Investigative Site Edmonton Alberta T6G 2B7 Canada Details
Novartis Investigative Site Toronto Ontario M5G 2M9 Canada Details
Novartis Investigative Site Bobigny Cedex 93009 France Details
Novartis Investigative Site Frankfurt 60590 Germany Details
Novartis Investigative Site Freiburg 79106 Germany Details
Novartis Investigative Site Budapest 1097 Hungary Details
Novartis Investigative Site Debrecen 4032 Hungary Details
Novartis Investigative Site Kaposvar 7400 Hungary Details
Novartis Investigative Site Szeged H 6725 Hungary Details
Novartis Investigative Site Firenze FI 50134 Italy Details
Novartis Investigative Site Reggio Calabria RC 89124 Italy Details
Novartis Investigative Site Roma RM 00161 Italy Details
Novartis Investigative Site Seoul Korea 05505 Korea, Republic of Details
Novartis Investigative Site Seoul 06351 Korea, Republic of Details
Novartis Investigative Site Malaga Andalucia 29010 Spain Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Madrid 28006 Spain Details
Novartis Investigative Site Gothenburg 413 45 Sweden Details
Novartis Investigative Site Stockholm SE-118 83 Sweden Details
Novartis Investigative Site Basel 4031 Switzerland Details
Novartis Investigative Site Geneve 1205 Switzerland Details
Novartis Investigative Site St. Gallen 9007 Switzerland Details
Novartis Investigative Site Bangkok 10330 Thailand Details
Novartis Investigative Site Bangkok 10700 Thailand Details
Novartis Investigative Site London EC1A 7BE United Kingdom Details
Novartis Investigative Site Wolverhampton WV10 0QP United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field